Skip to
  1. Homepage
  2. Research and trials
  3. Clinical trials
Search by disease/gene

Search by disease/gene

*
(*) mandatory field


 

Other search option(s)

138 matching term(s)

Caption : Recruiting trial = Recruiting trial
; Ongoing trial = Ongoing trial

    • AUSTRIA
    • STEIERMARK
    • GRAZ
    • Ongoing trial
    • Radiation therapy and combination chemotherapy in treating young patients with medulloblastoma, supratentorial primitive neuroectodermal tumor, or ependymoma (HIT 2000) (Phase III)
    • Medizinische Universität Graz
    • Klinische Abteilung für Pädiatrische Hämatologie/Onkologie
    • More details
    • AUSTRIA
    • TIROL
    • INNSBRUCK
    • SAPPHIRE : Efficacy and safety of AP 12009 (Trabedersen) in adult patients with recurrent or refractory Anaplastic Astrocytoma (WHO grade III) as compared to standard treatment with Temozolomide or BCNU : a randomized, actively controlled, open-label Phase III Study
    • Medizinische Universität Innsbruck
    • Universitätsklinik für Neurologie
    • More details
    • AUSTRIA
    • WIEN
    • WIEN
    • Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: aphase III study Intergroup Study (EORTC 22033-26033)
    • Medizinische Universität Wien
    • Universitätsklinik für Innere Medizin I
    • More details
    • AUSTRIA
    • WIEN
    • WIEN
    • Nordic Glioma study (Phase III)
    • Medizinische Universität Wien
    • Universitätsklinik für Innere Medizin I
    • More details
    • BELGIUM
    • ARRONDISSEMENT BRUSSELS-CAPITAL
    • NOT YET IDENTIFIED - BE
    • Recruiting trial
Ongoing trial
    • Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma.-BE
    • NOT YET IDENTIFIED - BE
    • More details
    • BELGIUM
    • ARRONDISSEMENT BRUSSELS-CAPITAL
    • NOT YET IDENTIFIED - BE
    • Recruiting trial
Ongoing trial
    • TAVAREC: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial (Phase II) - BE
    • NOT YET IDENTIFIED - BE
    • More details
    • BELGIUM
    • ARRONDISSEMENT BRUSSELS-CAPITAL
    • NOT YET IDENTIFIED - BE
    • Ongoing trial
    • Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter - a randomized multicenter, open-label, Phase II study - BE
    • NOT YET IDENTIFIED - BE
    • More details
    • BELGIUM
    • VLAAMS BRABANT
    • LEUVEN
    • Recruiting trial
Ongoing trial
    • Immunotherapy for relapsed or newly diagnosed malignant glioma.
    • University Hospitals Leuven - Gasthuisberg
    • Laboratory for Cell and Gene Therapy
    • More details
    • DENMARK
    • Hovedstaden
    • COPENHAGEN
    • Ongoing trial
    • A phase II trial with Bevacizumab and Irinotecan for patients with primary brain tumors and progression after standard therapy
    • Rigshospitalet
    • Department of Oncology
    • More details
    • DENMARK
    • Hovedstaden
    • COPENHAGEN
    • Ongoing trial
    • A phase II trial with Cetuximab, Bevacizumab and Irinotecan for patients with malignant glioblastomas and progression after radiation therapy and Temozolomide
    • Rigshospitalet
    • Department of Oncology
    • More details
    • DENMARK
    • Jylland
    • NOT YET IDENTIFIED - DK
    • Recruiting trial
Ongoing trial
    • Phase 1/2 Efficacy, Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, with Solid Tumours Eligible for Autologous Transplants - DK
    • NOT YET IDENTIFIED - DK
    • More details
    • FINLAND
    • Finland
    • HELSINKI
    • Ongoing trial
    • BNCT to treat glioma that has progressed following radiotherapy
    • HUCH - Helsinki University Central Hospital
    • Department of Oncology
    • More details
    • FRANCE
    • AQUITAINE
    • BORDEAUX
    • Recruiting trial
Ongoing trial
    • Phase II clinical trial for the Methodological Evaluation of Fluor 18 Labelled Fluoromisonidazole ([18F]-FMISO) Positon Emission Tomography-Computed Tomography (PET-CT) for Non Operated Glioblastoma
    • CHU de Bordeaux - Hôpital Saint André
    • Service d'oncologie médicale et de radiothérapie
    • More details
    • FRANCE
    • BRETAGNE
    • RENNES
    • Concomitant radiochemotherapy with topotecan in adult glioblastoma: a phase II study - Terminated -
    • CLCC Eugène Marquis
    • Département d'Oncologie Médicale
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • BOBIGNY
    • A Phase II multicenter study of immunotherapy with CpG-ODN in patients with glioblastoma -Terminated -
    • CHU Paris Seine-Saint-Denis - Hôpital Avicenne
    • Service de neurologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • BOBIGNY
    • Randomized Phase III Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma - Terminated -
    • CHU Paris Seine-Saint-Denis - Hôpital Avicenne
    • Service de neurologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • BOBIGNY
    • Glivec - Hydrea in recurrent glioblastoma (Phase II) - Terminated -
    • CHU Paris Seine-Saint-Denis - Hôpital Avicenne
    • Service de neurologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • BOBIGNY
    • Ongoing trial
    • REGAL: A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone - FR
    • CHU Paris Seine-Saint-Denis - Hôpital Avicenne
    • Service de neurologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • BOBIGNY
    • Recruiting trial
Ongoing trial
    • Radiotherapy and Temozolomide with or without Avastin for treatment of de novo glioblastoma (Phase III)
    • CHU Paris Seine-Saint-Denis - Hôpital Avicenne
    • Service de neurologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Gene therapy for glioblastoma in adult patients : Safety and efficacy evaluation of an in situ injection of recombinant retroviruses producing cells carrying the thymidine kinase gene of the Herpes Simplex type 1 virus, to be followed with the administration of Ganciclovir (Phase I-II)
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Laboratoire de biologie et thérapeutique des pathologies immunitaires
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Ongoing trial
    • EORTC protocol 26083 : Randomized phase II of CCNU (Lomustine) versus CCNU (Lomustine) - dasatinib in patients with recurrent glioblastoma
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Service de neurologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Chemotherapy study of temozolomide-bevacizumab treatment of supratentorial glioblastoma patients more than 70 years old with altered functional state (Phase II).
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Service de neurologie Mazarin
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Phase III study chemotherapy vs radiotherapy in low-grade glioma
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Service de neurologie Mazarin
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Recruiting trial
Ongoing trial
    • A Prospective, Multi-center Phase III Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed Glioblastoma Multiforme
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Service de neurologie Mazarin
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter - a randomized multicenter, open-label, Phase II study - FR
    • CHU Paris-GH La Pitié Salpêtrière-Charles Foix - Hôpital Pitié-Salpêtrière
    • Service de neurologie Mazarin
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • PARIS
    • Recruiting trial
Ongoing trial
    • Multicentric Randomized Phase II: Immunotherapy With CpG-ODN in Malignant Glioblastoma
    • CHU Paris-GH St-Louis Lariboisière F-Widal - Hôpital Lariboisière
    • Service de Neurologie
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • VILLEJUIF
    • Open Label, Pilot Phase II Study of Glivec in Children and Adolescents with Life Threatening Diseases Known to be associated with one or more Glivec-Sensitive Tyrosine Kinases - FR
    • CLCC Institut de cancérologie Gustave Roussy
    • Département de cancérologie de l'enfant et de l'adolescent
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • VILLEJUIF
    • Recruiting trial
Ongoing trial
    • Cooperative multicenter study for children and adolescents with low grade glioma - FR
    • CLCC Institut de cancérologie Gustave Roussy
    • Département de pédiatrie - UPRES EA 3535
    • More details
    • FRANCE
    • ILE-DE-FRANCE
    • VILLEJUIF
    • Recruiting trial
Ongoing trial
    • Phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with 1p/19q codeleted anaplastic glioma - FR
    • CLCC Institut de cancérologie Gustave Roussy
    • Service de radiothérapie
    • More details
    • FRANCE
    • LORRAINE
    • NANCY
    • Recruiting trial
Ongoing trial
    • SAPPHIRE : Efficacy and Safety of AP 12009 (Trabedersen) in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma as Compared to Standard Treatment With Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study
    • CHU de Nancy - Hôpital central
    • Unité d'oncologie
    • More details
    • FRANCE
    • MIDI-PYRENEES
    • TOULOUSE
    • Ongoing trial
    • PhaseI-II trial to assess the radiosensitizing effect of Zarnestra in patients with glioblastoma multiforme
    • CLCC Institut Claudius Regaud - IUCT Oncopole
    • Service de radiothérapie
    • More details
    • FRANCE
    • PAYS DE LA LOIRE
    • ANGERS
    • Glioblastoma treatment by peroperative or stereotactic implantation of biodegradable microspheres liberating a radiosensitizer antimetabolite (5-FU) : multicentric randomised IIb phasis study
    • CHU d'Angers
    • Ingénierie de la vectorisation particulaire
    • More details
    • FRANCE
    • PROVENCE-ALPES-COTE D'AZUR
    • MARSEILLE
    • Recruiting trial
Ongoing trial
    • First line chemotherapy with combination of Temozolomide (TMZ) and BCNU in newly diagnosed anaplastic oligodendrocytoma. A phase II study with translational molecular analysis
    • CHU de Marseille - Hôpital de la Timone
    • Service de neuro-oncologie
    • More details
    • FRANCE
    • PROVENCE-ALPES-COTE D'AZUR
    • MARSEILLE
    • Recruiting trial
Ongoing trial
    • Multicentric Randomized Phase II: Immunotherapy With CpG-ODN in Malignant Glioblastoma
    • CHU de Marseille - Hôpital de la Timone
    • Service de neuro-oncologie
    • More details
    • FRANCE
    • PROVENCE-ALPES-COTE D'AZUR
    • MARSEILLE
    • Ongoing trial
    • A randomized multicentric phase II trial immunotherapy of de novo glioblastoma by CpG-ODN
    • CHU de Marseille - Hôpital de la Timone
    • Service de neuro-oncologie
    • More details
    • FRANCE
    • PROVENCE-ALPES-COTE D'AZUR
    • MARSEILLE
    • Primary chemotherapy with temozolomide vs radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss a phase III study
    • CHU de Marseille - Hôpital de la Timone
    • Service de neuro-oncologie
    • More details
    • FRANCE
    • RHONE-ALPES
    • LYON
    • Recruiting trial
Ongoing trial
    • Randomized Phase III Study of Normal-Fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma
    • CLCC Léon Bérard
    • Neurooncologie
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • Recruiting trial
Ongoing trial
    • CORE - Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) -FR
    • NOT YET IDENTIFIED - FR
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • Recruiting trial
Ongoing trial
    • Cilengitide (EMD121974) in combination with irradiation in children and young adults with newly diagnosed diffuse intrinsic pontine glioma : Phase I study
    • NOT YET IDENTIFIED - FR
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • Recruiting trial
Ongoing trial
    • TEP-FET - Evaluation of a new tracer for positron emission tomography (PET), O-(2-[18F]-fluoroethyl)-l-tyrosine, or FET, in support of low-grade gliomas
    • NOT YET IDENTIFIED - FR
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • Recruiting trial
Ongoing trial
    • Open-label, combined dose-finding and efficacy-finding study of RO5323441 in combination with bevacizumab for patients with recurrent glioblastoma - FR
    • NOT YET IDENTIFIED - FR
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • Ongoing trial
    • Phase 1/2 Efficacy, Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, with Solid Tumours Eligible for Autologous Transplants - FR
    • NOT YET IDENTIFIED - FR
    • More details
    • FRANCE
    • RHONE-ALPES
    • NOT YET IDENTIFIED - FR
    • Ongoing trial
    • AVAGLIO: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Bevacizumab, Radiotherapy and Temozolomide (TMZ) Followed by Bevacizumab and TMZ, Versus Placebo Radiotherapy and TMZ Followed by Placebo and TMZ on Survival in Patients With Newly Diagnosed Glioblastoma (Phase III) - FR
    • NOT YET IDENTIFIED - FR
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Ongoing trial
    • A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • EORTC 26082-22081: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed Glioblastoma without methylation of the MGMT gene promoter - A randomized multicenter, open-label, phase II study - DE
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • DIRECTOR: Dose-intensified rechallenge with Temozolomide, one week on one week off versus three weeks on one week off in patients with progressive or recurrent Glioblastoma (Phase II)
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • APG101_CD_002: A Phase II, randomized, open-label, multi-centre study of weekly APG101 + Reirradiation versus Reirradiation in the treatment of patients with first or second progression of Glioblastoma
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • CATNON (EORTC 26053-22054) - Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted Anaplastic Glioma - DE
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • Phase 1b/2a study combining LY2157299 with standard Temozolomide-based Radiochemotherapy in patients with newly diagnosed malignant Glioma - DE
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • NOA-08/Methusalem: Randomized phase III trial of 1-week-on/1-week-off Temozolomide versus radiotherapy in elderly (older than age 65) patients with Anaplastic Astrocytoma or Glioblastoma - DE Completed
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Ongoing trial
    • EORTC 26052-22053 (RTOG 0525) : Phase III trial comparing conventional adjuvant Temozolomide with dose-intensive Temozolomide in patients with newly diagnosed Glioblastoma
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • EORTC 26081-22086 (CODEL): Phase III intergroup study of Radiotherapy versus Temozolomide alone versus Radiotherapy with concomitant and adjuvant Temozolomide for patients with 1p/19q codeleted Anaplastic Glioma - DE
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • TAVAREC (EORTC 26091) - Randomized trial assessing the significance of Bevacizumab in recurrent Grade II and Grade III Glioma (Phase II) - DE
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Ongoing trial
    • EORTC 26062-22061: A randomized phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients - DE
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • EORTC 26101: Randomized phase II trial exploring the sequence of Bevacizumab and Lomustine in patients with first recurrence of a Glioblastoma
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Ongoing trial
    • A Phase II, multicenter, randomized, double-blind study of LY2157299 monohydrate monotherapy or LY2157299 monohydrate Plus Lomustine therapy compared to Lomustine monotherapy in patients with recurrent Glioblastoma - DE
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • NONK-3/NOA-12: A Phase I/II, randomized, open label, multicentre study of BIBF1120 + Reirradiation versus Reirradiation in the treatment of patients with First or second progression of Glioblastoma
    • Universitätsklinikum Heidelberg
    • Abteilung für Neuroonkologie
    • More details
    • GERMANY
    • Baden-Württemberg
    • HEIDELBERG
    • Recruiting trial
Ongoing trial
    • CLEOPATRA: Randomized phase II study evaluating a Carbon Ion boost applied after combined radiochemotherapy with Temozolomide versus a Proton boost after radiochemotherapy with Temozolomide in patients with primary Glioblastoma
    • Universitätsklinikum Heidelberg
    • Klinik für Radioonkologie und Strahlentherapie
    • More details
    • GERMANY
    • Baden-Württemberg
    • ULM
    • Recruiting trial
Ongoing trial
    • The C-GBM Study: Prospective controlled phase II trial of Cabazitaxel in patients with Temozolomide refractory Glioblastoma Multiforme
    • Universitätsklinikum Ulm
    • Klinik für Innere Medizin III
    • More details
    • GERMANY
    • Bayern
    • AUGSBURG
    • Recruiting trial
Ongoing trial
    • SIOP-LGG-2004: Radiation therapy or combination Chemotherapy in treating Patients with clinically or radiologically progressive Low-Grade Gliomas
    • Klinikum Augsburg
    • I. Klinik für Kinder und Jugendliche
    • More details
    • GERMANY
    • Bayern
    • AUGSBURG
    • Ongoing trial
    • A Prospective, Multi-Center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM (Phase III)
    • Klinikum Augsburg
    • Neurochirurgische Klinik
    • More details
    • GERMANY
    • Bayern
    • REGENSBURG
    • SAPPHIRE: Efficacy and safety of AP 12009 (Trabedersen) in adult patients with recurrent or refractory Anaplastic Astrocytoma (WHO grade III) as compared to standard treatment with Temozolomide or BCNU (Phase III ) DE - Terminated
    • Universität Regensburg
    • Klinik und Poliklinik für Neurologie
    • More details
    • GERMANY
    • Bayern
    • REGENSBURG
    • Recruiting trial
Ongoing trial
    • EORTC 22033-26033: Primary chemotherapy with Temozolomide versus Radiotherapy in patients with low grade Gliomas after stratification for genetic 1p loss: A Phase III Study
    • Universität Regensburg
    • Klinik und Poliklinik für Neurologie
    • More details
    • GERMANY
    • Berlin
    • NOT YET IDENTIFIED - DE
    • Ongoing trial
    • A Phase 1/2 comparative study of the efficacy and safety of Plerixafor in addition to standard regimens for mobilization of haematopoietic stem cells into peripheral blood, and subsequent collection by apheresis, versus standard mobilization regimens alone in pediatric patients with Solid Tumours eligible for autologous transplants - DE
    • Not yet identified - DE
    • More details
    • GERMANY
    • Hamburg
    • HAMBURG
    • Recruiting trial
Ongoing trial
    • OSAG101-BSA05: Phase-III study of standard radiotherapy plus concomitant and adjuvant OSAG 101 (Theraloc®) plus temozolomide vs. standard radiotherapy plus concomitant and adjuvant temozolomide in patient with newly diagnosed, histological confirmed glioblastoma multiforme grade IV
    • UKE - Universitätsklinikum Hamburg-Eppendorf
    • Klinik und Poliklinik für Neurochirurgie
    • More details
    • GERMANY
    • Hamburg
    • HAMBURG
    • Recruiting trial
Ongoing trial
    • A prospective, multicenter phase III trial of NovoTTF-100A together with Temozolomide compared to Temozolomide alone in patients with newly diagnosed Glioblastoma Multiforme (GBM)
    • UKE - Universitätsklinikum Hamburg-Eppendorf
    • Klinik und Poliklinik für Neurochirurgie
    • More details
    • GERMANY
    • Hamburg
    • HAMBURG
    • Ongoing trial
    • HIT 2000 Interim: Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma (Phase III)
    • UKE - Universitätsklinikum Hamburg-Eppendorf
    • Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie
    • More details
    • GERMANY
    • Hessen
    • FRANKFURT AM MAIN
    • Ongoing trial
    • GERT: Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme (Phase I-II)
    • Markus-Krankenhaus
    • Radiologisches Institut
    • More details
    • GERMANY
    • Niedersachsen
    • GÖTTINGEN
    • Ongoing trial
    • Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Gliomas or Diffuse Intrinsic Pontine Glioma (Phase III)
    • Universitätsmedizin Göttingen
    • Abteilung Pädiatrie I - Hämatologie/Onkologie und Immunologie/Rheumatologie
    • More details
    • GERMANY
    • Niedersachsen
    • GÖTTINGEN
    • Ongoing trial
    • HIT-HGG-2007: International cooperative phase II trials of the HIT-HGG study group for the treatment of high grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in children and adolescents 3 years and older up to 18 years
    • Universitätsmedizin Göttingen
    • Abteilung Pädiatrie I - Hämatologie/Onkologie und Immunologie/Rheumatologie
    • More details
    • GERMANY
    • Niedersachsen
    • GÖTTINGEN
    • Ongoing trial
    • HIT-HGG-CilMetro: Cilengitide and Metronomic Temozolomide for relapsed or refractory high grade Gliomas or Diffuse Intrinsic Pontine Gliomas in children and adolescents - Prospective non- randomised phase II study
    • Universitätsmedizin Göttingen
    • Abteilung Pädiatrie I - Hämatologie/Onkologie und Immunologie/Rheumatologie
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • BONN
    • Phase III Study on the effectiveness of OSAG 101 (Theraloc®) in newly diagnosed Intrinsic Pontine Gliomas of children and adolescents - Terminated
    • Universitätsklinikum Bonn
    • Abteilung für Pädiatrische Hämatologie/ Onkologie
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • BONN
    • Recruiting trial
Ongoing trial
    • CENTRIC: A Multicenter, open-label, controlled Phase III Study, assessing efficacy and safety of Cilengitide in combination with standard treatment (Temozolomide with concomitant radiation therapy, followed by Temozolomide maintenance therapy) versus standard treatment alone for patients with newly diagnosed Glioblastoma Multiforme and methylated MGMT gene promoter
    • Universitätsklinikum Bonn
    • Klinik und Poliklinik für Neurologie
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • BONN
    • Ongoing trial
    • CeTeG: Efficacy and safety study of Lomustine/Temozolomide combination therapy versus standard Temozolomide therapy for newly diagnosed MGMT-methylated Glioblastoma patients (Phase III)
    • Universitätsklinikum Bonn
    • Klinik und Poliklinik für Neurologie
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • BONN
    • Recruiting trial
Ongoing trial
    • ML21965/Glarius - Randomized, open-label, multicentre phase II study to compare the effect of Avastin (Bevacizumab) + Irinotecan versus Temozolomide, in combination with conventional involved field radiotherapy, in patients with newly diagnosed Glioblastoma and a non-methylated MGMT promoter.
    • Universitätsklinikum Bonn
    • Klinik und Poliklinik für Neurologie
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • BONN
    • NOA-05: Phase II trial of Procarbazine and Lomustine in Gliomatosis cerebri - Terminated
    • Universitätsklinikum Bonn
    • Klinik und Poliklinik für Neurologie
    • More details
    • GERMANY
    • Nordrhein-Westfalen
    • ESSEN
    • Recruiting trial
Ongoing trial
    • HIT-REZ 2005: Therapy-Optimization trial and phase II study for the treatment of relapsed or refractory of primitive neuroectodermal brain tumors and ependymomas in children and adolescents
    • Universitätsklinikum Essen
    • Klinik für Kinderheilkunde III - Abteilung für pädiatrische Hämatologie und Onkologie
    • More details
    • GERMANY
    • Sachsen
    • DRESDEN
    • Ongoing trial
    • AVAGLIO: A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and radiotherapy followed by placebo and temozolomide in patients with newly diagnosed glioblastoma - DE
    • Universitätsklinikum Carl Gustav Carus an der TU Dresden
    • Klinik und Poliklinik für Neurochirurgie
    • More details
    • GERMANY
    • Schleswig-Holstein
    • KIEL
    • Ongoing trial
    • REGAL: A Phase III, randomised, parallel group, multicentre study in recurrent Glioblastoma patients to compare the efficacy of Cediranib (RECENTIN, AZD2171) monotherapy and the combination of Cediranib with Lomustine to the efficacy of Lomustine alone - DE
    • Universitätsklinikum Schleswig-Holstein - Campus Kiel
    • Klinik für Neurochirurgie
    • More details
    • IRELAND
    • County Dublin
    • DUBLIN
    • Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma - IE
    • Our Lady's Children's Hospital
    • National Oncology/ Bone Marrow Transplant Centre and Haematology Department
    • More details
    • IRELAND
    • County Dublin
    • NOT YET IDENTIFIED - IE
    • Recruiting trial
Ongoing trial
    • A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas - IE
    • NOT YET IDENTIFIED - IE
    • More details
    • ITALY
    • EMILIA ROMAGNA
    • BOLOGNA
    • Ongoing trial
    • Phase I/II study on concomitant and adjuvant temozolomide and radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM
    • Azienda USL di Bologna Ospedale Bellaria
    • U. O. di Oncologia Medica
    • More details
    • ITALY
    • EMILIA ROMAGNA
    • NOT YET IDENTIFIED - IT
    • Recruiting trial
Ongoing trial
    • CORE - Cilengitide in subjects with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter - a multicenter, open-label Phase II study, investigating two cilengitide regimens in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) - IT
    • NOT YET IDENTIFIED - IT
    • More details
    • ITALY
    • EMILIA ROMAGNA
    • NOT YET IDENTIFIED - IT
    • Ongoing trial
    • Randomized, non comparative phase II trial with bevacizumab and fotemustine in the treatment of recurrent glioblastoma
    • NOT YET IDENTIFIED - IT
    • More details
    • ITALY
    • LOMBARDIA
    • MILANO
    • Ongoing trial
    • Second italian protocol of diagnosis and treatment of childhood ependymoma
    • Fondazione IRCCS Istituto Nazionale dei Tumori
    • Unità di Neuro-Oncologia Pediatrica
    • More details
    • NETHERLANDS
    • Groningen
    • GRONINGEN
    • Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma
    • UMCG - Universitair Medisch Centrum Groningen
    • More details
    • NETHERLANDS
    • Limburg
    • MAASTRICHT
    • Recruiting trial
Ongoing trial
    • Randomized Assessment of Conventional Neuronavigation Versus Intraoperative MRI for the Neurosurgical Treatment of Glioblastomas
    • AZM - Academisch Ziekenhuis Maastricht
    • Afdeling Neurochirurgie
    • More details
    • NETHERLANDS
    • Noord-Holland
    • AMSTERDAM
    • Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
    • VUmc - VU medisch centrum
    • More details
    • NETHERLANDS
    • Utrecht
    • NOT YET IDENTIFIED - NL
    • Ongoing trial
    • Phase 1/2 Efficacy, Safety of Plerixafor in Addition to Standard Regimens for Mobilisation of Haematopoietic Stem Cells into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilisation Regimens Alone in Paediatric Patients, with Solid Tumours Eligible for Autologous Transplants
    • NOT YET IDENTIFIED - NL
    • More details
    • NETHERLANDS
    • Zuid-Holland
    • DEN HAAG
    • Ongoing trial
    • Cognitieve Rehabilitatie van Glioom Patiënten
    • Medisch Centrum Haaglanden, locatie Westeinde
    • Afdeling Neurologie
    • More details
    • NETHERLANDS
    • Zuid-Holland
    • ROTTERDAM
    • Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma
    • Erasmus MC - Erasmus Medisch Centrum
    • Afdeling Kinderoncologie en -hematologie
    • More details
    • NETHERLANDS
    • Zuid-Holland
    • ROTTERDAM
    • Ongoing trial
    • Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    • Erasmus MC Kanker Instituut
    • Afdeling Neuro-Oncologie
    • More details
    • POLAND
    • Lublin
    • LUBLIN
    • SAPPHIRE : Efficacy and Safety of AP 12009 (Trabedersen) in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma as Compared to Standard Treatment With Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study - PL - Terminated
    • Medical university of Lublin
    • Samodzielny Publiczny Szpital Kliniczny Nr 4
    • More details
    • POLAND
    • Warszawa
    • WARSAW
    • Recruiting trial
Ongoing trial
    • Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma - PL
    • The Children's Memorial Health Institute CMHI (IP-CZD)
    • Klinika Onkologii IP-CZD
    • More details
    • PORTUGAL
    • NORTE
    • PORTO
    • Recruiting trial
Ongoing trial
    • Cooperative Multicenter Study for Children and Adolescents With Low Grade Glioma - PT
    • Centro Hospitalar de S. João, EPE
    • Unidade de Hematologia e Oncologia Pediátrica
    • More details
    • SPAIN
    • Cantabria
    • SANTANDER
    • SAPPHIRE : Efficacy and Safety of AP 12009 (Trabedersen) in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma as Compared to Standard Treatment With Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study - ES (terminated)
    • HUMV - Hospital Universitario Marqués de Valdecilla
    • Servicio de Neurocirugía (HUMV)
    • More details
    • SPAIN
    • Castilla - León
    • SALAMANCA
    • Recruiting trial
Ongoing trial
    • A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma - ES
    • Complejo Asistencial Universitario de Salamanca
    • Servicio de Hematología
    • More details
    • SPAIN
    • Cataluña
    • BADALONA
    • Ongoing trial
    • A Phase II Open Label Randomised Multicentric Study in Patients With Unresectable Glioblastoma Using Neo-adjuvant Treatment With Two Cycles of Temozolomide Previous Temozolomide Plus Radiation Therapy and Adjuvant Temozolomide vs. Neo-adjuvant Treatment With Two Cycles of Temozolomide Plus Bevacizumab Previous Temozolomide, Bevacizumab and Radiation Therapy and Adjuvant Temozolomide
    • ICO Badalona
    • Servico de Oncología Médica
    • More details
    • SPAIN
    • Cataluña
    • BADALONA
    • An Open Label Non- Randomized Multicentric Phase II Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients (Phase II) (completed)
    • ICO Badalona
    • Servico de Oncología Médica
    • More details
    • SPAIN
    • Cataluña
    • BADALONA
    • Recruiting trial
Ongoing trial
    • Clinical Trial Phase IIB randomized, multicenter, of continuation or non-continuation with 6 cycles of temozolomide after the first 6 cycles of standard first-line treatment in patients with glioblastoma - ES
    • ICO Badalona
    • Servico de Oncología Médica
    • More details
    • SPAIN
    • Cataluña
    • BADALONA
    • Recruiting trial
Ongoing trial
    • The CATNON Intergroup trial: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma - ES
    • ICO Badalona
    • Servico de Oncología Radioterápica
    • More details
    • SPAIN
    • Cataluña
    • BARCELONA
    • Recruiting trial
Ongoing trial
    • Cilengitide for Subjects With Newly Diagnosed Glioblastoma Multiforme and Methylated MGMT Gene Promoter - A Multicenter, Open-Label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone
    • Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
    • Oncología - Terapéutica experimental
    • More details
    • SPAIN
    • Cataluña
    • BARCELONA
    • Recruiting trial
Ongoing trial
    • A Phase Ib/II, Multi-center, Open-label Study of Single-agent INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma - ES
    • Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
    • Oncología - Terapéutica experimental
    • More details
    • SPAIN
    • Cataluña
    • BARCELONA
    • Recruiting trial
Ongoing trial
    • CheckMate 143: A Randomized Phase 2b, Open Label Study of Nivolumab or Nivolumab in Combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM) - ES
    • Fundació Institut de Recerca Hospital Universitari Vall d'Hebron
    • Oncología - Terapéutica experimental
    • More details
    • SPAIN
    • Cataluña
    • BARCELONA
    • SAPPHIRE : Efficacy and Safety of AP 12009 (Trabedersen) in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma as Compared to Standard Treatment With Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study - ES (terminated)
    • Hospital Universitari General Vall d'Hebron
    • Servicio de Neurocirugía
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • EFFECTS STUDY: An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC) (Phase III) - ES (Completed)
    • Hospital Universitari Sant Joan de Déu
    • Unidad de enfermedades metabólicas hereditarias
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • Recruiting trial
Ongoing trial
    • A Phase II Open-Label, Randomized, Multi-Centre Comparative Study of Bevacizumab-Based Therapy in Paediatric Patients With Newly Diagnosed Supratentorial High-Grade Glioma - ES
    • Hospital Universitari Sant Joan de Déu
    • Servicio de oncología pediátrica
    • More details
    • SPAIN
    • Cataluña
    • ESPLUGUES DE LLOBREGAT
    • Phase II, Single Arm, Open Label Clinical Trial With Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas (Completed)
    • Hospital Universitari Sant Joan de Déu
    • Servicio de oncología pediátrica
    • More details
    • SPAIN
    • Madrid
    • MADRID
    • SAPPHIRE : Efficacy and Safety of AP 12009 (Trabedersen) in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma as Compared to Standard Treatment With Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study - ES (terminated)
    • Hospital Universitario 12 de Octubre
    • Servicio de Neurocirugía (H.U. 12 de Octubre)
    • More details
    • SPAIN
    • Madrid
    • MADRID
    • Recruiting trial
Ongoing trial
    • A Prospective Multicenter, Open Label, Phase II Pilot Clinical Trial to Evaluate Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation - ES
    • Hospital Universitario 12 de Octubre
    • Unidad Multidisciplinar de Neurooncología
    • More details
    • SPAIN
    • Madrid
    • NOT YET IDENTIFIED - ES
    • Ongoing trial
    • AVAGLIO: A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Bevacizumab, Radiotherapy and Temozolomide (TMZ) Followed by Bevacizumab and TMZ, Versus Placebo Radiotherapy and TMZ Followed by Placebo and TMZ on Survival in Patients With Newly Diagnosed Glioblastoma (Phase III) - ES
    • NOT YET IDENTIFIED - ES
    • More details
    • SPAIN
    • Madrid
    • NOT YET IDENTIFIED - ES
    • Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma - ES (completed)
    • NOT YET IDENTIFIED - ES
    • More details
    • SPAIN
    • Madrid
    • NOT YET IDENTIFIED - ES
    • Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study - ES (Completed)
    • NOT YET IDENTIFIED - ES
    • More details
    • SPAIN
    • Madrid
    • NOT YET IDENTIFIED - ES
    • A Single Arm Phase II Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme (completed)
    • NOT YET IDENTIFIED - ES
    • More details
    • SPAIN
    • Madrid
    • NOT YET IDENTIFIED - ES
    • Ongoing trial
    • Phase 1b/2a Study Combining LY2157299 With Standard Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma - ES
    • NOT YET IDENTIFIED - ES
    • More details
    • SPAIN
    • Madrid
    • NOT YET IDENTIFIED - ES
    • Ongoing trial
    • A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma
    • NOT YET IDENTIFIED - ES
    • More details
    • SPAIN
    • Madrid
    • NOT YET IDENTIFIED - ES
    • Ongoing trial
    • A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma - ES
    • NOT YET IDENTIFIED - ES
    • More details
    • SPAIN
    • Navarra
    • PAMPLONA
    • Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope (completed)
    • Clínica Universidad de Navarra
    • Servicio de Hematología y Hemoterapia (CUN)
    • More details
    • SPAIN
    • País Vasco
    • BARAKALDO
    • SIOP: Study of Combined Modality Treatment in Childhood Ependymoma (Phase II) (completed)
    • Hospital Universitario Cruces - Osakidetza
    • Unidad de Oncología Pediátrica
    • More details
    • SPAIN
    • País Vasco
    • BARAKALDO
    • SAPPHIRE : Efficacy and Safety of AP 12009 (Trabedersen) in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma as Compared to Standard Treatment With Temozolomide or BCNU: A Randomized, Actively Controlled, Open Label Clinical Phase III Study - ES (terminated)
    • Hospital Universitario Cruces - Osakidetza
    • Servicio de Neurocirugía (H. de Cruces - Osakidetza)
    • More details
    • UNITED KINGDOM
    • Avon
    • BRISTOL
    • Ongoing trial
    • MCRN059 (CRAD001M2301): A randomised, double-blind, placebo-controlled study of RAD001 in the treatment of patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex, TSC (phase III)
    • Level 6, University Hospitals Bristol Education Centre
    • Bristol Child Neuroscience (CNS)
    • More details
    • UNITED KINGDOM
    • Greater London
    • LONDON
    • Ongoing trial
    • A phase II open-label, randomized, multi-centre comparative study of bevacizumab-based therapy in paediatric patients with newly diagnosed supratentorial high-grade glioma - UK
    • Great Ormond Street Hospital for Children, NHS Foundation Trust
    • Haematology and oncology department
    • More details
    • UNITED KINGDOM
    • Greater London
    • LONDON
    • Recruiting trial
Ongoing trial
    • A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM) - UK
    • King's College Hospital
    • Department of Medical Oncology
    • More details
    • UNITED KINGDOM
    • Greater London
    • SURREY
    • Recruiting trial
Ongoing trial
    • FGFR Study: Proof-of-concept study of AZD 4547 in patients with FGFR1 or FGFR2 amplified tumours - UK
    • The Royal Marsden
    • Department of Medicine
    • More details
    • UNITED KINGDOM
    • Greater Manchester
    • NOT YET IDENTIFIED - UK
    • Recruiting trial
Ongoing trial
    • An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors
    • NOT YET IDENTIFIED - UK
    • More details
    • UNITED KINGDOM
    • Greater Manchester
    • NOT YET IDENTIFIED - UK
    • Ongoing trial
    • SAPPHIRE: Efficacy and safety of AP 12009 (Trabedersen) in adult patients with recurrent or refractory Anaplastic Astrocytoma (WHO grade III) as compared to standard treatment with Temozolomide or BCNU (Phase III ) - UK
    • NOT YET IDENTIFIED - UK
    • More details
    • UNITED KINGDOM
    • Greater Manchester
    • NOT YET IDENTIFIED - UK
    • Ongoing trial
    • Phase III intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with concomitant and adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma - UK
    • NOT YET IDENTIFIED - UK
    • More details
    • UNITED KINGDOM
    • Greater Manchester
    • NOT YET IDENTIFIED - UK
    • Ongoing trial
    • EORTC 26082 - 22081: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter - a randomized multicenter, open-label, Phase II study - UK
    • NOT YET IDENTIFIED - UK
    • More details
    • UNITED KINGDOM
    • Greater Manchester
    • NOT YET IDENTIFIED - UK
    • Ongoing trial
    • RTOG: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma - UK
    • NOT YET IDENTIFIED - UK
    • More details
    • UNITED KINGDOM
    • Greater Manchester
    • NOT YET IDENTIFIED - UK
    • Ongoing trial
    • CENTRIC: Cilengitide in subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter - a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radiation therapy, followed by temozolomide maintenance therapy) versus standard treatment alone - UK
    • NOT YET IDENTIFIED - UK
    • More details
    • UNITED KINGDOM
    • Lothian
    • EDINBURGH
    • Recruiting trial
Ongoing trial
    • TAVAREC: Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial (Phase II) - UK
    • Edinburgh Cancer Centre
    • More details
    • UNITED KINGDOM
    • Lothian
    • EDINBURGH
    • Recruiting trial
Ongoing trial
    • The CATNON Intergroup trial: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma - UK
    • Edinburgh Cancer Centre
    • More details
    • UNITED KINGDOM
    • Nottinghamshire
    • NOTTINGHAM
    • CNS 1997 02: Study of Paediatric Low Grade Gliomas (Phase III) (Completed)
    • Queen's Medical Centre
    • Child Health Department
    • More details
    • UNITED KINGDOM
    • Tyne & Wear
    • NEWCASTLE UPON TYNE
    • CNS 2007 04: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide With Radiotherapy in Diffuse Pontine Gliomas - UK (Completed)
    • Royal Victoria Infirmary
    • Sir James Spence Institute of Child Health
    • More details
    • UNITED KINGDOM
    • West Midlands
    • BIRMINGHAM
    • Ongoing trial
    • CNS 2007 09: CCLG Observational Study of the Outcome of Ependymoma in Infants Diagnosed Before Their Third Birthday (Phase III)
    • Birmingham Children's Hospital NHS Foundation Trust
    • Department of Oncology
    • More details
    • UNITED KINGDOM
    • West Midlands
    • BIRMINGHAM
    • CNS 2005 03: Phase II Study of High-Dose Methotrexate in Children with Residual Ependymoma (Completed)
    • Birmingham Children's Hospital NHS Foundation Trust
    • Department of Oncology
    • More details
    • UNITED KINGDOM
    • West Yorkshire
    • LEEDS
    • Recruiting trial
Ongoing trial
    • CNS 2004 03: Cooperative Multicentre Study For Children And Adolescents With Low Grade Glioma (Phase III) (SIOP-LGG 2004)
    • St James's University Hospital
    • Regional Paediatric Oncology Unit
    • More details
    • UNITED KINGDOM
    • West Yorkshire
    • LEEDS
    • Ongoing trial
    • CNS 2001 04: Phase II study of Intravenous Etoposide in Patients with Relapsed Ependymoma
    • St James's University Hospital
    • Regional Paediatric Oncology Unit
    • More details